Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Cartesian Therapeutics, Inc. (NASDAQ: RNAC)
RNAC Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-49.80%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
400%
RNAC Stock Analysis
RNAC
PE Ratio:
RNAC
PEG Ratio:
Not Available
RNAC
Forward EPS Growth (12 month):
0.00%
RNAC
PS Ratio:
103.6
RNAC
PSG Ratio:
-2.9
RNAC
Forward Revenue Growth (12 month):
-35.20%
RNAC Articles
No data was found